Reckitt Beats Quarterly Sales Estimates on Growth Abroad

The consumer goods giant Reckitt Benckiser Group plc has reported a quarterly sales beat, driven by a 10th consecutive quarter of double-digit expansion in emerging markets. The company achieved a like-for-like net revenue increase of 5.4% for the quarter ending December 31, exceeding the 4.7% growth anticipated by analysts. This growth comes as the firm continues to transition its portfolio toward high-growth, high-margin brands. As part of its strategic realignment, the manufacturer of Durex and Lysol finalized the $4.8 billion divestment of its Essential Home division to Advent International at the end of the year, while maintaining a 30% equity stake. This move aligns with broader industry trends seen at competitors such as NESTLE SA - NEW and Unilever PLC, which are also focusing on core high-performance brands. CEO Kris Licht has identified China and India as critical "must-win" markets for the company's long-term strategy. Licht emphasized that the growth of middle-class households in these regions now surpasses the combined totals of Europe and the United States. > "The runway for growth is so significant, and from a standpoint of where we have to win, this is absolutely a must-win set of markets for us." Revenue in emerging markets, which accounts for approximately 42% of the group's core net revenue, rose by 17.2%. Conversely, the European market experienced a quarterly decline of 4.5%. Analysts at Barclays noted that the emerging markets segment is providing a vital growth engine for the group at a time when category growth in developed markets remains sluggish. Despite the strong sales performance, shares of the United Kingdom-based firm opened lower. The company expects its core businesses to grow between 4% and 5% in 2026, though it warned that the trading environment in Europe is likely to remain difficult. Additionally, the company noted that its seasonal over-the-counter business, which includes brands like Lemsip and Nurofen, may be impacted in early 2026 by a milder cold and flu season. This cautious outlook follows similar comments from Haleon plc, which recently reported underwhelming results due to a less severe flu season.